ClinicaliQ Trial Snapshot
- Multi-modular Chimeric Antigen Receptor Targeting GD2 in Neuroblastoma — Active Not Recruiting • Phase I • NCT05990751.
- A trial testing a new engineered cell therapy for children with difficult-to-treat neuroblastoma, focusing on safety and feasibility.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
MAGNETO is a single-centre, non-randomised, open label Phase I clinical trial of an Advanced Therapy Investigational Medicinal Product (ATIMP) in children and teenagers aged 1-16 years with relapsed or refractory neuroblastoma. The study will assess the feasibility of generating the ATIMP (GD2 CAR T cells) and the safety of administering the ATIMP in patients with relapsed or refractory neuroblastoma. Conditions: Neuroblastoma Interventions: GD2 CAR T cells Lead Sponsor: University College, London Planned Enrollment: 12 participants